Clinical nuclear medicine · 2015
18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
Оценочное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bailly Matthieu, Ribeiro Maria Joao Santiago, Vercouillie Johny, Hommet Caroline, Gissot Valérie, Camus Vincent, Guilloteau Denis
Аннотация
OBJECTIVE: The aim of this study is to compare regional cerebral metabolic rate of glucose metabolism and amyloid-β density in patients with Alzheimer disease (AD), mild cognitive impairment (MCI), and healthy elderly subjects.
METHODS: Eighteen patients (including 6 AD, 5 amnestic MCI, and 7 controls) were enrolled at the University Hospital of Tours, France, and submitted to clinical, neuropsychological, and MRI examinations. PET images using F-florbetapir (266 MBq) and F-FDG (185 MBq) were acquired. SUV ratios in specific regions were defined using PMOD3.2 software.
RESULTS: The mean values of F-FDG SUV ratio were significantly lower in frontal, anterior cingulate, and temporal regions in MCI patients than in normal elderly (-15%, -22%, and -11%, respectively). Alzheimer disease patients showed global cerebral metabolic rate of glucose metabolism decrease, especially in parietal and precuneus regions (-15% and -13% compared with healthy control subjects). Only precuneus cortex showed an increased F-florbetapir uptake in AD. There was no other significant regional difference in the amyloid-β density.
CONCLUSIONS: In this study, we observed regional brain metabolic changes between MCI, AD, and controls, whereas only precuneus showed an increased amyloid-β density in AD. F-florbetapir PET analysis needs to be visual and global, whereas F-FDG analysis can be regional.
METHODS: Eighteen patients (including 6 AD, 5 amnestic MCI, and 7 controls) were enrolled at the University Hospital of Tours, France, and submitted to clinical, neuropsychological, and MRI examinations. PET images using F-florbetapir (266 MBq) and F-FDG (185 MBq) were acquired. SUV ratios in specific regions were defined using PMOD3.2 software.
RESULTS: The mean values of F-FDG SUV ratio were significantly lower in frontal, anterior cingulate, and temporal regions in MCI patients than in normal elderly (-15%, -22%, and -11%, respectively). Alzheimer disease patients showed global cerebral metabolic rate of glucose metabolism decrease, especially in parietal and precuneus regions (-15% and -13% compared with healthy control subjects). Only precuneus cortex showed an increased F-florbetapir uptake in AD. There was no other significant regional difference in the amyloid-β density.
CONCLUSIONS: In this study, we observed regional brain metabolic changes between MCI, AD, and controls, whereas only precuneus showed an increased amyloid-β density in AD. F-florbetapir PET analysis needs to be visual and global, whereas F-FDG analysis can be regional.